Moderna: sales plummet in Q1

(CercleFinance.com) - Moderna reports total Q1 sales of $167m, less than a tenth the Q1 2023 figure ($1,862m).


The laboratory posted an operating loss of $1,266m, i.e. a net loss of $1,175m, way off the $79m profit recorded twelve months ago.

EPS came in at -$3.07 (though ahead of expectations), compared with +$0.2 a year earlier.

As we anticipate the launches of our Spikevax 2024-2025 formula and RSV vaccine, we are demonstrating financial discipline and have intensified our efforts on the creation and use of AI technologies to further streamline operations and improve productivity, it said.

The company confirms its expectation of around $4bn in sales for 2024 for its respiratory franchise, and now forecasts net sales of around $0.3bn in H1, reflecting the seasonal nature of the respiratory business.


Copyright (c) 2024 CercleFinance.com. All rights reserved.